Skip to content

Rescue Emetic Therapy for Children Having Elective Surgery

Rescue Emetic Therapy for Children Having Elective Therapy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01067677
Acronym
RETCHES
Enrollment
0
Registered
2010-02-11
Start date
2010-02-28
Completion date
2014-02-28
Last updated
2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Nausea and Vomiting, Rescue Emetic Therapy

Keywords

PONV, Post operative nausea and vomiting, rescue emetic therapy

Brief summary

To compare ondansetron, metoclopramide, diphenhydramine, and placebo in order to determine which anti-emetic is most efficacious as a rescue therapy for pediatric patients ages 3-18 who have post-operative vomiting after a standardized prophylactic regimen of ondansetron and dexamethasone. We hypothesize that anti-emetics with a different mechanism of action than the prophylactic regimen will be the most effective rescue therapy in children having surgery in an ambulatory surgery center. 1. Problem: Despite commonly-used anti-emetics for prophylaxis, some children still go on to develop post-operative vomiting (POV). Goal: To determine which anti-emetic--ondansetron, metoclopramide, diphenhydramine, or placebo--is most efficacious for pediatric patients in this situation. 2. Hypothesis: Anti-emetic medications that have a different mechanism of action than the prophylactic regimen will be the most efficacious rescue therapy. 3. Hypothesis: Metoclopramide at the dose of 0.5 mg/kg (max dose 20 mg) will be more effective than ondansetron, diphenhydramine, or placebo as rescue therapy.

Interventions

0.5 mg/kg for rescue after PONV

DRUGOndansetron

0.1 mg/kg (max 4 mg0

DRUGdiphenhydramine

0.25 mg/kg (max 25 mg)

DRUGSaline

equal volume (5 ml)as experimental rescue medications

Sponsors

Franklyn Cladis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

1. Pediatric patients 3-17 years old 2. Patients scheduled for tonsillectomy and/or adenoidectomy (with and without myringotomy) , or dental restoration, 3. Patients receiving a general anesthetic (inhaled agent without nitrous oxide) with POV prophylaxis with two agents (ondansetron and dexamethasone) 4. Post operative vomiting in PACU or second stage recovery requiring antiemetic rescue.

Exclusion criteria

1. Vomiting in the past 24 hours or antiemetics in previous 24 hours 2. Allergy or sensitivity to ondansetron, dexamethasone, metoclopramide, or diphenhydramine 3. Patients with diabetes 4. Patients with seizures 5. Patients receiving a benzodiazepine premedication

Design outcomes

Primary

MeasureTime frame
Primary-Incidence of POV after rescue antiemetic in PACU, car ride home, day of surgery, and POD #1 and 248 hrs

Secondary

MeasureTime frame
Secondary - a. Discharge times48 hrs
Adverse events (headaches, sedation, dystonic reaction, dry mouth)48 hrs
POV risk factors. age, personal or family history of PONV, history of motion sickness, personal or family history of smoking48 hrs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026